Search

Displaying results 8301 - 8310 of 9667 in total
  1. Drug

    Envudeucitinib

    go.drugbank.com/drugs/DB21716
    Investigational

    Envudeucitinib has a monoisotopic molecular weight of 426.23 Da.

  2. Drug

    Zemprocitinib

    go.drugbank.com/drugs/DB21719
    Experimental

    Zemprocitinib has a monoisotopic molecular weight of 345.13 Da.

  3. Drug

    SNS01-T

    go.drugbank.com/drugs/DB17302
    Investigational

    SNS01-T is a gene therapy nanoparticle. … It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.

  4. Drug

    PLX51107

    go.drugbank.com/drugs/DB17543
    Investigational

    PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family.

  5. Drug

    PF-04856884

    go.drugbank.com/drugs/DB17550
    Investigational

    [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).

  6. Drug

    Dapansutrile

    go.drugbank.com/drugs/DB16130
    Investigational

    Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

  7. Drug

    Desidustat

    go.drugbank.com/drugs/DB16135
    Investigational

    Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).

  8. Drug

    Bimagrumab

    go.drugbank.com/drugs/DB12584
    Investigational

    Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis

  9. Drug

    XPro1595

    go.drugbank.com/drugs/DB16454
    Investigational

    XPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.

  10. Drug

    Emrusolmin

    go.drugbank.com/drugs/DB13927
    Investigational

    Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.